NYSE:BHVNBiotechs
Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide?
Biohaven (BHVN) drew fresh investor attention today after appointing John Yetimoglu, an AI focused investment leader, to its Board of Directors. The move signals a stronger push into data driven drug discovery and development.
See our latest analysis for Biohaven.
Biohaven’s short term share price return has softened, with the 30 day share price return down 12.35%, although the 90 day share price return is up 38.24% and year to date the share price return is up 25.74%. Over a longer horizon,...